Table I.
STC1 expression and the prognosis of BC subtypes.
| Author, year | Country | Breast cancer subtype | Outcome | Expression level of STC1 in BC | Predictive value of STC1 expression in BC | (Refs.) |
|---|---|---|---|---|---|---|
| McCudden et al 2004 | Canada | All subtypes | Tumor size, blood and lymphatic invasion | High | Poor prognosis | (24) |
| Wascher et al 2003 | America | All subtypes | Tumor size, number of positive lymph nodes, T stagea, M stagea, N stagea, overall AJCC stagea | NA | Poor prognosis | (26) |
| Chang et al 2015 | Australia | All subtypes | Tumor growth, metastasis | High | Poor prognosis | (22) |
| Zandberga et al 2017 | Latvia | Basal | RFS, OS, DMFS | NA | Poor prognosis | (25) |
| Luminal A | RFS, OS, DMFS | NA | NC | |||
| Luminal B | RFS, OS, DMFS | NA | Poor prognosis | |||
| HER2+ | RFS, OS, DMFS | NA | NC | |||
| Han et al 2016 | Korea | TNBC | RFS, OS | High | Poor prognosis | (19) |
| Korea | Non-TNBC | RFS, OS | High | NC | ||
| Jeon et al 2016 | Korea | TNBC | RFS, OS | High | Poor prognosis | (21) |
| Luminal | RFS, OS | Low | NC | |||
| HER2+ | RFS, OS | Low | NC | |||
| Welcsh et al 2002 | America | All subtypes | Level of BRCA1 and STC1 expression | Low | Good prognosis | (30) |
| Joensuu et al 2008 | Finland | Hormone receptor-positive | Recurrence, metastasis | High | Good prognosis | (29) |
| Brantley et al 2018 | America | ER+/TAM+ | Recurrence | Higher | Good prognosis | (27) |
| ER−/TAM− | Recurrence | Lower | Good prognosis |
a
Amin MB, Edge S, Greene F, et al: AJCC Cancer Staging Manua[M]. 8th ed. New York: Springer, 2017. STC1, stanniocalcin-1; BC, breast cancer; TNBC, triple-negative breast cancer; DMFS, distant metastasis-free survival; NC, no correlation; NA, not available, TAM−, tamoxifen-untreated; TAM+, tamoxifen-treated; ER+, estrogen receptor-positive; HER2+, human epidermal growth factor receptor 2; OS, overall survival; RFS, relapse-free survival.